Theravance Biopharma, Inc.
TBPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.21 | -0.01 | 0.63 | -0.39 |
| FCF Yield | -0.88% | 37.59% | 9.70% | -0.24% |
| EV / EBITDA | -262.27 | 4.25 | -30.65 | -62.62 |
| Quality | ||||
| ROIC | -5.40% | -0.53% | -4.29% | -4.80% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -1.80 | 3.79 | -3.17 | 0.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.80% | 14.62% | 10.35% | 7.83% |
| Free Cash Flow Growth | -103.13% | 383.38% | 4,041.30% | 79.04% |
| Safety | ||||
| Net Debt / EBITDA | 56.21 | -3.15 | 5.02 | -1.58 |
| Interest Coverage | -11.27 | -4.11 | -22.45 | -14.31 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 75.31 | 89.80 | 328.44 |